(NASDAQ: NAMS) Newamsterdam Pharma Co Nv's forecast annual revenue growth rate of 267.98% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.78%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.5%.
Newamsterdam Pharma Co Nv's revenue in 2026 is $8,092,045.On average, 19 Wall Street analysts forecast NAMS's revenue for 2026 to be $3,501,721,829, with the lowest NAMS revenue forecast at $351,439,277, and the highest NAMS revenue forecast at $7,530,841,647. On average, 18 Wall Street analysts forecast NAMS's revenue for 2027 to be $20,602,231,077, with the lowest NAMS revenue forecast at $2,824,424,229, and the highest NAMS revenue forecast at $75,484,136,108.
In 2028, NAMS is forecast to generate $50,586,934,549 in revenue, with the lowest revenue forecast at $15,111,888,905 and the highest revenue forecast at $131,969,034,576.